Vizsgálati helyszín
Asante Rogue Regional Medical Center
Medford, Oregon 97504, Egyesült ÁllamokMég nincs intézményhez kötve
- 18futó vizsgálat
- 4lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 23 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis16 vizsgálat
- 2. fázis2 vizsgálat
- 1. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz14 vizsgálat
- Toboroz4 vizsgálat
- Lezárult3 vizsgálat
- Felfüggesztve1 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- National Cancer Institute (NCI)9 vizsgálat
- Hoffmann-La Roche3 vizsgálat
- Eli Lilly and Company2 vizsgálat
- Alliance for Clinical Trials in Oncology1 vizsgálat
- Canadian Cancer Trials Group1 vizsgálat
- és még 7
Futó vizsgálatok
Toboroz
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Alison D. Savage (principal investigator)
Fut, nem toboroz
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
NCT06524375· 2. fázis· Genentech, Inc.· Forrás
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Contact: Alison Savage (principal investigator)
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Alison D. Savage (principal investigator)
Toboroz
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Alison D. Savage (principal investigator)
Fut, nem toboroz
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548· 1. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
NCT03933826· University of Washington· Forrás
Fut, nem toboroz
Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
NCT03697148· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
NCT02115282· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
NCT01575548· 3. fázis· National Cancer Institute (NCI)· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek